The Uncommon Conversations in Drug Development LIVE series, hosted by the scientific and medical experts at Worldwide Clinical Trials, is more than your average networking event. Designed with emerging to midsized biopharma and pharma in mind, it’s an uncommon environment for our peers to collaborate, meet like-minded execs, and gain introductions to those who have successfully faced the same challenges.
A Game of Chess? Or Draughts? Historical Sponsor/CRO relationships can be characterized by an analogy to the game of draughts: a predictable, slow-paced, capacity-driven business model with limited moves and transactional exchanges. Can a modern paradigm more closely align with chess: intuitive, strategic, and cognizant of the impact of each move to multiple downstream events?
Join leading Sponsor and CRO experts for a lively exploration of how you can make the right moves toward transforming a transactional-based relationship to a “value-added,” highly functional, visionary approach to your clinical development.
WHEN: 14 November 2018 | 16:00 -18:00
UNCOMMON VENUE: Babraham Research Campus | Kings Hedges, Cambridge Hall | Cambridge, UK
AGENDA: Cocktail Reception & 45-Minute Moderated Panel
MODERATOR: Peter Jenner, Professor of Pharmacology at King’s College London
Founders, clinical and operations leaders and their teams seeking opportunities to mix it up and gain insight into the inside track…the know-how to avoid pitfalls, advice from their peers that have made mistakes, learned from them and then succeeded.
MBChB MRCP FFPM
Worldwide Clinical Trials
Farid Kahn, M.D.
Protein Technologies LTD.
MB BS MRCP
Chief Medical Officer,
Combebelle Life &
Independent Development Consultant
Beverley Patterson, Ph.D.
Clinical Science Director,
Your form has been successfully submitted! Thank you for your interest in Worldwide Clinical Trials. We will respond to your inquiry as soon as possible.
ABOUT WORLDWIDE CLINICAL TRIALS
Founded by physicians committed to advancing medical science, Worldwide is out to change how the world experiences CROs – in the best possible way. From early phase and bioanalytical sciences through late phase, post-approval and real-world evidence, we provide world-class, full-service drug development services.
With infrastructure and talent spanning 60+ countries, we execute predictable, successful studies with operational excellence across a range of therapeutic areas, including central nervous system, cardiovascular, metabolic, general medicine, oncology and rare diseases. We never compromise on science or safety. We’re never satisfied with the status quo. We’re the Cure for the Common CRO. For more information, visit www.worldwide.com.